Document
IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2018 Exhibit - EX2018 Transcript of December 29, 2023 Deposition of John Bantle, MD (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2018 Exhibit - EX2018 Transcript of December 29, 2023 Deposition of John Bantle, MD (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2486 Exhibit - EX2486 US Food Drug Administration, DrugsFDA, Avandia (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2486 Exhibit - EX2486 US Food Drug Administration, DrugsFDA, Avandia (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2501 Exhibit - EX2501 Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 Feb 5, 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2501 Exhibit - EX2501 Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 Feb 5, 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2377 Exhibit - EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKANA™ Canagliflozin for the Treatment of Adults with Type 2 Diabetes,” httpswwwprnewswire...
Cite Document
IPR2023-00724, No. 2377 Exhibit - EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKANA™ Canagliflozin for the Treatment of Adults with Type 2 Diabetes,” httpswwwprnewswirecomnews releasesu
+ More Snippets
Document
IPR2023-00724, No. 2099 Exhibit - EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, Stroke, 52e364–e467 2021 (P.T....
Cite Document
IPR2023-00724, No. 2099 Exhibit - EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, Stroke, 52e364–e467 2021 (P.T.A.B. Jan.
+ More Snippets
Document
IPR2023-00724, No. 2398 Exhibit - EX2398 Januvia® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2398 Exhibit - EX2398 Januvia® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2400 Exhibit - EX2400 Janumet® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2400 Exhibit - EX2400 Janumet® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2475 Exhibit - EX2475 Mounjaro Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2475 Exhibit - EX2475 Mounjaro Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2389 Exhibit - EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adherence, Circulation, 2009 119233028 3035 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2389 Exhibit - EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adherence, Circulation, 2009 119233028 3035 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2437 Exhibit - EX2437 US Food Drug Administration, DrugsFDA, Tanzeum® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2437 Exhibit - EX2437 US Food Drug Administration, DrugsFDA, Tanzeum® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2470 Exhibit - EX2470 Rybelsus Prescribing Information rev Jan 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2470 Exhibit - EX2470 Rybelsus Prescribing Information rev Jan 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2369 Exhibit - EX2369 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17...
Cite Document
IPR2023-00724, No. 2369 Exhibit - EX2369 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2358 Exhibit - EX2358 Mayo Clinic, “Type 2 diabetes – Diagnosis Treatment,” httpswwwmayoclinicorgdiseases conditionstype 2 diabetes diagnosis treatmentdrc 20351199,...
Cite Document
IPR2023-00724, No. 2358 Exhibit - EX2358 Mayo Clinic, “Type 2 diabetes – Diagnosis Treatment,” httpswwwmayoclinicorgdiseases conditionstype 2 diabetes diagnosis treatmentdrc 20351199, last updated
+ More Snippets